Hem › Crohns sjukdom › New York › New York City
Kliniska studier för Crohns sjukdom i New York City, NY
35 studier för Crohns sjukdom söker deltagare vid platser i och runt New York City (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
RekryterarFas 2
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RekryterarFas 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RekryterarFas 3
- New York Gastroenterology Associates ( Site 0253), New York
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
RekryterarFas 3
- NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York
- Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York
- New York Gastroenterology Associates ( Site 5013), New York
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RekryterarFas 4
- New York Gastroenterology Associates, New York
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RekryterarFas 2
- Northwell Health-Lenox Hill Hospital /ID# 265527, New York
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RekryterarFas 3
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RekryterarFas 2
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
RekryterarFas 3
- New York Gastroenterology Associates, New York
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RekryterarFas 2/3
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Weill Cornell Medical College, New York
- Lenox Hill Hospital, New York
- och 1 fler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RekryterarFas 3
- New York Gastroenterology Associates, New York
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RekryterarFas 3
- Manhattan Clinical Research, LLC-Site Number: 8400069, New York
- NYU Langone Health-Site Number: 8400091, New York
- Columbia University Medical Center-Site Number: 8400138, New York
- och 2 fler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RekryterarFas 3
- NYU Langone Health-Site Number: 8400091, New York
- Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040, New York
- New York Gastroenterology Associates-Site Number: 8400009, New York
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
RekryterarFas 3
- Icahn School of Medicine at Mount Sinai /ID# 254880, New York
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RekryterarFas 3
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RekryterarFas 4
- NYU Langone Health, New York
Standardized Microbiota Transplant Therapy in Crohn's Disease
RekryterarFas 2
- NYU Langone Health, New York
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
RekryterarFas 3
- New York Gastroenterology Associates, New York
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RekryterarFas 3
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center/New York Presbyterian, New York
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RekryterarFas 3
- Weill Cornell Medicine, New York
Behavioral Therapy for Crohn's Disease
Rekryterar
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Rekryterar
- NYU Langone Health, New York
- Cornell University, New York
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RekryterarObservationsstudie
- New York University, New York
Low Dose IL-2 for the Treatment of Crohn's Disease
RekryterarFas 1/2
- Mount Sinai, New York
Autologous Stem Cell Transplant for Crohn's Disease
RekryterarFas 2
- Icahn School of Medicine at Mount Sinai, New York
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
RekryterarFas 3
- Icahn School of Medicine at Mount Sinai /ID# 262216, New York
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RekryterarFas 3
- New York Presbyterian Hospital, New York
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
RekryterarFas 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RekryterarFas 3
- Columbia University Medical Center, New York-Presbyterian Hospital, New York
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
RekryterarFas 4
- Columbia University Medical Center, New York
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
Rekryterar
- Weill Cornell Medical College, New York
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RekryterarFas 2
- Mirador Therapeutics Selected Site, New York
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
RekryterarObservationsstudieFriska volontärer välkomna
- Icahn School of Medicine at Mount Sinai, New York
Treatment of Moderate to Severe Refractory Crohn's Disease
RekryterarFas 1/2
- Mount Sinai Health Systems, New York
Helmsley 3.0: Abbreviated MRE
RekryterarObservationsstudie
- NYU Langone, New York
Crohns sjukdom-studier i andra städer
- Boston, MA19 studier
- Miami, FL19 studier
- Cleveland, OH19 studier
- St. Louis, MO19 studier
- Tyler, TX17 studier
- Houston, TX17 studier
- Orlando, FL17 studier
- Atlanta, GA17 studier
- San Antonio, TX15 studier
- San Diego, CA15 studier
- Los Angeles, CA15 studier
- Colorado Springs, CO13 studier
Andra studier i New York City
- Bröstcancer136 studier
- Icke-småcellig lungcancer121 studier
- Cancer (alla typer)109 studier
- Prostatacancer103 studier
- Metastaserande cancer93 studier
- Kolorektal cancer78 studier
- Äggstockscancer69 studier
- Lungcancer60 studier
- Multipelt myelom60 studier
- Bukspottkörtelcancer60 studier
- Endometriecancer52 studier
- Akut myeloid leukemi51 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.